A first-in-human clinical trial of an immune rejuvenation therapy designed to restore the function of worn-out T cells is expected to begin later this year, building on research led by UCL scientists into the mechanisms of immune ageing.

The Phase 1 trial will focus on exhausted or senescent T cells, which accumulate with age and in chronic disease and become less effective at coordinating immune protection.

Researchers hope that metabolically resetting these cells may help the immune system regain characteristics associated with younger, healthier immune responses. The work may have clinical utility for diseases such as cancer, HIV and dementia.

Our immune system protects us from infection, cancer and disease. However, as we age, some immune cells become exhausted and lose their ability to function effectively. This process, known as immune ageing, can leave people more vulnerable to illness and less able to respond to health challenges.

The new therapy, developed by biotech company SenTcell founded by Dr Alessio Lanna (UCL Medicine), is designed to rejuvenate these worn-out immune cells. Rather than attacking diseased cells directly, it works by restoring the immune system’s natural ability to recognise and respond to threats.

The treatment is a liquid formulation administered by intramuscular injection, similar to many commonly used vaccines. Once delivered, it is designed to reprogramme key pathways that drive immune dysfunction, helping immune cells regain characteristics of younger, healthier cells.

The goal is to improve immune resilience, enhance protection against disease and ultimately support healthier ageing.

Dr Lanna said: “People living with HIV are now able to live long and healthy lives thanks to major advances in treatment, but many still experience features of accelerated immune ageing. Similar patterns of immune dysfunction are also seen in cancer and other chronic diseases.

“This trial is an important step towards testing whether we can safely rejuvenate exhausted immune cells and restore aspects of healthy immune function. Our goal is to help establish immune rejuvenation as a new way of treating diseases linked to immune ageing and dysfunction.”

The trial builds on research suggesting that some dysfunctional T cells – a type of white blood cell that helps coordinate the body’s immune response – can be restored to a more youthful, functional state. Researchers are focusing on CD4+ T cells, often described as the “conductors” of the immune system because they help direct other immune cells to respond to infection, cancer and disease.

Inside every cell, chromosomes are protected by structures called telomeres, which sit at their ends like protective caps. Telomeres help shield genetic material from damage and gradually shorten as cells divide over time, making them a well-established marker of biological ageing.

Previous laboratory studies suggest that rejuvenated CD4+ T cells may be able to release telomere-containing structures into the bloodstream. Researchers have termed these structures “telomere rivers” and are investigating whether they could help explain how rejuvenated immune cells influence the health and function of other tissues throughout the body. This idea remains under active investigation and has not yet been demonstrated in humans.

The research programme has received support through the Medicines and Healthcare products Regulatory Agency’s (MHRA) Innovative Licensing and Access Pathway (ILAP), recognising its potential to address significant unmet needs associated with age-related immune decline and immune dysfunction.

UCL researchers are preparing for Phase 1 of the trial, which will carefully select adult participants and is expected to focus initially on people with evidence of immune dysfunction, including immune ageing and chronic viral infection. Participants will undergo detailed immune profiling before and after treatment.

Investigators will look at whether the therapy can restore features of healthy immune function. As an early-stage trial, the primary goals are safety and biological activity rather than demonstrating clinical benefit.

If successful, the programme could establish immune rejuvenation as a new therapeutic approach: restoring the immune system’s protective capacity instead of targeting each pathogen or disease process separately.

Researchers believe the strategy could eventually have relevance for conditions characterised by immune exhaustion, including chronic infections, autoimmune disease and cancer, while also informing broader efforts to improve healthy ageing.

Weightlifting can improve memory and mental health in older women, whether they lift heavier or lighter weights, a clinical trial has found.

The study suggests structured exercise could offer a non-drug way to help protect the ageing mind.

As people age, physical abilities often decline and the risk of cognitive impairment rises.

Women can also face a higher risk of depression and anxiety later in life because of menopause, hormonal changes and shifting social factors.

Over time, poor mental health can speed up physical and cognitive decline.

Medical professionals often recommend cardiovascular and resistance training to help preserve physical independence.

Beyond building muscle and strength, lifting weights may also help protect the brain.

The research team recruited 120 women with an average age of 68 who were not taking part in any structured exercise programmes.

Before the intervention, independent cardiologists screened the volunteers using diagnostic stress tests to make sure they could take part safely.

The researchers then divided the women into three equal groups based on their baseline physical strength to ensure a balanced comparison.

The first group followed a resistance training programme using heavier weights for eight to 12 repetitions.

The second performed the same exercises using slightly lighter weights for 10 to 15 repetitions. The third acted as a control group and remained sedentary throughout the trial.

For three months, the active groups visited the university fitness facility three mornings a week.

Under the direct supervision of qualified fitness experts, participants completed three sets of eight different full-body exercises. These included weight machines and free weights, with movements such as chest presses, leg extensions, seated rows and bicep curls.

As the women grew stronger over the 12 weeks, supervisors progressively increased the weight they lifted.

This ensured participants stayed within their assigned repetition range while maintaining proper breathing and movement technique. Researchers also told all participants not to start any new exercise outside the laboratory setting.

The scientists carried out a broad set of cognitive and psychological tests before the programme began and again shortly after it ended.

They used the Montreal Cognitive Assessment to measure spatial skills, short-term memory and language processing.

The team also used several standardised surveys to track symptoms of geriatric depression and general anxiety.

Other tests assessed executive function, the mental processes involved in planning, focusing attention and multitasking.

In the Trail Making Test, the women had to connect a scattered sequence of numbers and letters as quickly as possible to assess cognitive flexibility.

In another verbal test, they had to name as many words beginning with the letter F, or as many animals as possible, within 60 seconds.

The researchers also used a computerised Stroop test to assess inhibitory control. In this visual test, the women saw words such as “red” or “black” displayed in conflicting ink colours, such as green.

They had to suppress the automatic urge to read the word and instead press a button matching the ink colour.

After the three-month intervention, both groups of weightlifters showed clear improvements in their test scores.

Their performance on the overall cognitive assessment rose, and their reaction times in executive function tests fell substantially.

The control group showed no such improvements, and in some categories their mental performance worsened slightly.

The structured exercise also reduced the severity of mood disorders among the active participants.

Scores for depressive symptoms fell by roughly 34 per cent in the lower repetition group and 24 per cent in the higher repetition group. Anxiety scores fell by more than 40 per cent in both groups.

The researchers said these improvements met the threshold for a clinically meaningful difference.

In practical terms, that means the psychological benefits were large enough for the women to notice in their daily emotional state.

The trial found no major differences in outcomes between the two repetition strategies, suggesting both intensities worked equally well against cognitive decline.

The study has several caveats that may shape future research into the neurological benefits of structured exercise.

The testing relied heavily on self-reported psychological surveys, which can be affected by subjective bias or temporary changes in mood.

The team also did not closely track differences in the women’s light daily physical activity outside the gym.

The researchers also said the social structure of the fitness programme may have contributed to the emotional benefits.

For 12 weeks, the active participants exercised in a shared, supportive environment, with regular contact with peers and supervisors.

This kind of consistent social interaction can help reduce loneliness and provide psychological relief.

Future trials will need to isolate whether different exercise durations or extra social interaction change these positive neural effects.

Even so, the results suggest resistance training could offer an accessible way to help treat mild cognitive and mood problems.

Regular weightlifting may benefit the mind as well as the muscles in older adults.

Women with osteoporosis may be more likely to carry a gene linked to Alzheimer’s, according to new research.

Scientists found that APOE4, the most common genetic risk factor for Alzheimer’s, can weaken bone quality in women, even when standard scans appear normal.

The study, carried out by researchers at the Buck Institute for Research on Ageing in California, US, and UC San Francisco, suggests the gene may damage bone at a microscopic level long before any visible signs.

These changes can emerge as early as midlife and remain invisible to routine imaging tests used to assess bone strength.

The findings suggest a link between Alzheimer’s risk and skeletal health and could help pave the way for earlier detection of both conditions.

Professor Birgit Schilling, a senior author of the study, said: “What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch.

“APOE4 is quietly disrupting the very cells responsible for keeping bone strong – and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”

Doctors have long observed that people with Alzheimer’s suffer higher rates of bone fractures, while osteoporosis in women is known to be one of the earliest predictors of the disease.

Now scientists believe they may have uncovered why.

Researchers led by Dr Charles Schurman carried out a detailed analysis of proteins in aged mouse bone and found that tissue was unusually rich in molecules linked to neurological disease, including those associated with Alzheimer’s.

In particular, long-lived bone cells known as osteocytes showed elevated levels of APOE, with levels twice as high in older female mice compared with younger or male animals.

Further experiments using genetically modified mice revealed that APOE4 had a strong and sex-specific impact on both bone and brain tissue.

The disruption at the protein level was even greater in bone than in the brain.

However, the bone structure itself appeared completely normal under scans.

Instead, the gene interfered with a key maintenance process inside bone cells, preventing them from repairing microscopic channels that keep bones strong and resilient.

When this process breaks down, bones become more fragile even if they look healthy on standard imaging.

These results suggest bone cells could potentially act as early biological warning signs of cognitive decline in women carrying APOE4.

Professor Lisa Ellerby, another senior author, said: “We think targeting these cells may open a new front in preserving bone quality in this population.”

Experts say the findings highlight the need to view the body as an interconnected system rather than treating diseases in isolation.

Dementia, of which Alzheimer’s is the most common form, remains one of the UK’s biggest health challenges.

Around 900,000 people are currently living with the condition, a figure expected to rise to 1.6 million by 2040.

It is already the leading cause of death, responsible for more than 74,000 deaths each year.